MA House, Senate approve extra $58M for expanded regional transit service
Mass. House and Senate finalized the state budget for fiscal 2024, with $150M for regional transit including the Cape Cod Regional Transit Authority.
Source: yahoo.com
Page 10 - Expanded Access News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Expanded Access. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Expanded Access Today - Breaking & Trending Today
Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.
Cyclo Therapeutics, Inc. , a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today...
Source: marketscreener.com
Phase 1 Results Are "Extraordinary," Says Chairman Of Scientific Advisory Board As Biomedical Company Preps Phase 2 Trial For MS Treatment - Bayer (OTC:BAYRY), Sanofi (NASDAQ:SNY)
Tiziana Life Sciences (NASDAQ: TSLA) has presented data from its clinical trial showing that five of its six patients with an advanced stage of multiple sclerosis (MS) have shown a reduction in microglia activity,
Source: benzinga.com
IAEA requests access to inspect ZNPP reactor building roofs
Experts from the International Atomic Energy Agency (IAEA) have asked for expanded access to verify that any explosive devices are absent from the rooftops of reactor buildings at the Russia-occupied Zaporizhzhya Nuclear Power Plant (ZNPP), the agency said in a statement on July 5.
Source: yahoo.com
Cyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1
– Data published in official journal of Molecular Genetics and Metabolism Reports: Evidence of a change in cholesterol homeostasis in peripheral organs and the brain after the initial infusion Trappsol® Cyclo™ was detected in the CSF Completers had an 88.9% improvement in at least two domains of the 17-Domain Niemann-Pick Type C1 Clinical Severity Scale (17D-NPC-CSS) Improvement in Scale Assessment and Rating of Ataxia (SARA) score for the mean score in 7 of 8 domains at Week 48 compared with baseline Demonstrated a favorable benefit-risk profile
Source: marketscreener.com